IT1208 / IDAC Theranostics, Ono Pharma - LARVOL DELTA

Transient depletion of CD4+ cells induces remodeling of the TCR repertoire in gastrointestinal cancer. (PubMed, Cancer Immunol Res) - "To investigate the clonal T-cell responses following transient CD4+ cell depletion in patients with cancer, we conducted a temporal analysis of the T-cell receptor (TCR) repertoire in the first-in-human clinical trial of IT1208, a defucosylated humanized monoclonal anti-CD4...These results suggested that the clonal replacement of the TCR repertoire induced by transient CD4+ cell depletion was accompanied by the expansion of tumor-reactive T-cell clones which mediated anti-tumor responses. Our findings propose beneficial remodeling of the TCR repertoire following transient CD4+ cell depletion and provide novel insight into the anti-tumor effects of monoclonal anti-CD4 treatment in patients with cancer."

Journal • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Oncology • Solid Tumor

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. (PubMed, J Immunother Cancer) - "IT1208 monotherapy successfully depleted CD4 T cells with a manageable safety profile and encouraging preliminary efficacy signals, which warrants further investigations, especially in combination with immune checkpoint inhibitors."

Clinical • IO Biomarker • Journal • P1 data • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Immune Modulation • Inflammation • Oncology • Solid Tumor

Anti-CD4 monoclonal antibody immunotherapy exerts an antitumor effect by replacing the T cell receptor repertoire in patients with gastrointestinal cancer (AACR 2019) - "IT1208 treatment depleted CD4+ T cells from the blood and tumor. This depletion promoted the replacement of CD4+ and CD8+ T cell repertoire systemically. The IT1208 treatment-induced increase of tumor-associated CD8+ T cell clones may be associated with its anti-tumor effect in cancer patients."

Clinical • Late-breaking abstract